Defining Best Practices for Biosimilar Development


The global market for biosimilar drugs totaled more than $3 billion in 2016 and is expected to skyrocket to more than $10 billion by 2021, according to market research data. BioAgilytix’s Arno Kromminga, Ph.D. sat down with AAPS Newsmagazine discuss how the AAPS Ligand-Binding Assay Bioanalytical (LBABFG) and Biosimilars focus groups created the Biosimilars Action Program Committee (APC) to identify the bioanalytical challenges unique to biosimilar development and recommend practices to address these challenges.

Click for full article

Featured Expert

Pharmacokinetics & Pharmacodynamics​

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.
220328 Adleverage_Scientific Icon Illustrations_#46-65_CO_Per FIles